The vaccine single dose Sputnik Light show a 70% efficiency against the Delta variant of the coronavirus three months after the injection, as reported on Wednesday by the Russian Direct Investment Fund (RDIF), citing the developer of the immunizer, the center gamelea, also from Russia.
The data published on the website medRxiv, were based on the results of a study of 28,000 participants who received one dose of this immunizer, compared with a control group of 5.6 million individuals who were not vaccinated, the RDIF reported.
The data comes at a time when the country is facing an increase in infections and doubts about vaccines among its population, as it struggles to compete with more established vaccines developed by companies Pfizer, Modern and AstraZeneca, each with a production of hundreds of millions of doses.
Countries around the world are administering or considering the possibility of administering third doses of the Pfizer or Moderna vaccines, or of applying boosters to part of their population, particularly the immunosuppressed and the elderly, although there is no consensus among scientists on to what extent it should be administered, Reuters reported.
Applied as a booster for other vaccines, “Sputnik Light would be almost as effective against the Delta variant as the Russian flagship vaccine Sputnik V of two injections, “said in a statement the RDIF, which markets Sputnik V internationally. The RDIF stated that Sputnik Light would be more than 83% effective against contagions and more than 94% against hospitalizations.
For its part, Kirill Dmitriev, RDIF director, told Reuters that he hoped that Sputnik Light would eventually become Russia’s main coronavirus vaccine. “We believe that Sputnik Light could be the main vaccine within a year, when many people just need to be vaccinated again or have had the disease and do not need Sputnik V,” said Dmitriev.